Postural tachycardia syndrome (POTS) and antiphospholipid syndrome (APS) : What do we know so far?

被引:3
作者
Noureldine, H. A. [1 ]
El Hasbani, G. [2 ]
Eldine, M. Nour [1 ]
Nour-Eldine, W. [3 ]
Taher, A. [4 ]
Uthman, I [2 ]
机构
[1] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Byblos, Lebanon
[2] Amer Univ Beirut, Dept Internal Med, Med Ctr, Beirut, Lebanon
[3] Hamad Bin Khalifa Univ, Qatar Fdn, Neurol Disorders Res Ctr, Qatar Biomed Res Inst, Doha, Qatar
[4] Amer Univ Beirut, Dept Internal Med, Div Hematol & Med Oncol, Med Ctr, Beirut, Lebanon
关键词
Antiphospholipid syndrome; Postural orthostatic tachycardia    syndrome; Autonomic dysfunction; Antiphospholipid antibodies; Cytokines; Anticoagulation; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTONOMIC DYSFUNCTION; HUGHES-SYNDROME; DERMATOLOGICAL MANIFESTATIONS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; ANGIOTENSIN-II; C1Q RECEPTORS; NEUROPATHY;
D O I
10.1016/j.neurol.2021.10.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As part of the non-criteria clinical manifestations, postural orthostatic tachycardia syndrome (POTS), a multisystem autonomic dysfunction, can co-exist with antiphospholipid syndrome (APS). Several pieces of evidence hint on the autoimmune basis of POTS, and its possible association with several autoimmune diseases, including APS. Indeed, the evidence exists in the etiologies, symptomatology, and treatment options. Although infections, viral ones in particular, stress, and pregnancy are etiologies to both POTS and APS, the exact pathophysiological connection is still to be studied taking into consideration the activity of cytokines in both diseases. Nevertheless, certain immunomodulatory treatments used for the catastrophic or obstetrical forms of APS, such as intravenous immunoglobulins (IVIG) and steroids, have been also used for the treatment of POTS resistant to classical treatments. Therefore, our review aims to highlight the association between POTS and APS, shedding light on the common etiologies explaining the pathophysiology of the two disorders, the diagnostic approach to POTS as a possible clinical criterion of APS, and the treatment of APS in the context of treating POTS. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 37 条
  • [31] Post-thrombotic syndrome prevention - do we really know the predictive factors?
    Urbanek, Tomasz
    PHLEBOLOGIE, 2019, 48 (04) : 245 - 250
  • [32] Quantitative serum proteomic analysis for biomarker discovery in post-COVID-19 postural orthostatic tachycardia syndrome (PC-POTS) patients
    Ryu, Taekyung
    Adler, Brittany L.
    Jeong, Seeun Judy
    Lee, David C.
    Hoke, Ahmet
    Na, Chan Hyun
    Chung, Tae
    AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2025, 258
  • [33] Safety and Efficacy of Mesenchymal Stromal Cells and Other Cellular Therapeutics in Rheumatic Diseases in 2022: A Review of What We Know So Far
    Gilkeson, Gary S.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (05) : 752 - 765
  • [34] Hughes syndrome/APS. 30 years on, what have we learnt? Opening talk at the 14th International Congress on antiphospholipid antibodies Rio de Janiero, October 2013
    Hughes, Graham R. V.
    LUPUS, 2014, 23 (04) : 400 - 406
  • [35] Validation of symptom measures in patients under investigation for postural orthostatic tachycardia syndrome (POTS): The Orthostatic Grading Scale (OGS) and the Symptom Screen for Small-fiber Polyneuropathy (SSS)
    Knoop, Iris
    Jones, Annie S. K.
    Gall, Nicholas
    Chilcot, Joseph
    Pascoe, William
    Moss-Morris, Rona
    AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2023, 250
  • [36] International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management
    Giacomelli, Roberto
    Afeltra, Antonella
    Alunno, Alessia
    Baldini, Chiara
    Bartoloni-Bocci, Elena
    Berardicurti, Onorina
    Carubbi, Francesco
    Cauli, Alberto
    Cervera, Ricard
    Ciccia, Francesco
    Cipriani, Paola
    Conti, Fabrizio
    De Vita, Salvatore
    Di Benedetto, Paola
    Doria, Andrea
    Drosos, Alexandros A.
    Favalli, Ennio Giulio
    Gandolfo, Saviana
    Gatto, Mariele
    Grembiale, Rosa Daniela
    Liakouli, Vasiliki
    Lories, Rik
    Lubrano, Ennio
    Lunardi, Claudio
    Margiotta, Domenico Paolo Emanuele
    Massaro, Laura
    Meroni, Pierluigi
    Minniti, Antonia
    Navarini, Luca
    Pendolino, Monica
    Perosa, Federico
    Pers, Jacques-Olivier
    Prete, Marcella
    Priori, Roberta
    Puppo, Francesco
    Quartuccio, Luca
    Ruffatti, Amelia
    Ruscitti, Piero
    Russo, Barbara
    Sarzi-Puttini, Piercarlo
    Shoenfeld, Yehuda
    Somarakis, George A.
    Spinelli, Francesca Romana
    Tinazzi, Elisa
    Triolo, Giovanni
    Ursini, Francesco
    Valentini, Gabriele
    Valesini, Guido
    Vettori, Serena
    Vitali, Claudio
    AUTOIMMUNITY REVIEWS, 2017, 16 (09) : 911 - 924
  • [37] How do we classify patients suspected of having Sjogren's syndrome? The histological evolution of the various classification criteria and what will come next
    Manthorpe, R
    AKTUELLE RHEUMATOLOGIE, 2005, 30 (01) : 32 - 37